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Abstract
Background: Patients with rare diseases face health disparities and are often challenged to find accurate information
about their condition. We aimed to use the best available evidence and community partnerships to produce patient
education materials for congenital hypogonadotropic hypogonadism (CHH) and the olfacto-genital (Kallmann)
syndrome (i.e., CHH and defective sense of smell), and to evaluate end-user acceptability. Expert clinicians, researchers
and patients co-created the materials in a multi-step process. Six validated algorithms were used to assess reading level
of the final product. Comprehensibility and actionability were measured using the Patient Education Materials
Assessment Tool via web-based data collection. Descriptive statistics were employed to summarize data and thematic
analysis for analyzing open-ended responses. Subsequently, translation and cultural adaption were conducted by
clinicians and patients who are native speakers.
Results: Co-created patient education materials reached the target 6th grade reading level according to 2/6 (33%)
algorithms (range: grade 5.9–9.7). The online survey received 164 hits in 2 months and 63/159 (40%) of eligible patients
completed the evaluation. Patients ranged in age from 18 to 66 years (median 36, mean 39 ± 11) and 52/63 (83%), had
adequate health literacy. Patients scored understandability at 94.2% and actionability at 90.5%. The patient education
materials were culturally adapted and translated into 20 languages (available in Additional file 1).
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Conclusions: Partnering with patients enabled us to create patient education materials that met patient- identified
needs as evidenced by high end-user acceptability, understandability and actionability. The web-based evaluation was
effective for reaching dispersed rare disease patients. Combining dissemination via traditional healthcare professional
platforms as well as patient-centric sites can facilitate broad uptake of culturally adapted translations. This process may
serve as a roadmap for creating patient education materials for other rare diseases.
Keywords: Congenital hypogonadotropic hypogonadism, Kallmann syndrome, Rare diseases, E-health, Community
based participatory research, Patient education, Patient participation, Patient-centered care, Nursing
Background
The landmark 2009 report from the European Organization
for Rare Diseases (EURORDIS) brought to light the many
challenges faced by patients with rare diseases [1]. Delays in
diagnosis, difficulty finding information about their condi-
tion and inadequate access to expert care are frequent
patient experiences. Indeed, some have posited that living
with a rare disease places one in the realm of health dispar-
ities [2]. Physical and psychological morbidity can be
significant and feelings of isolation and powerlessness can
further undermine quality of life [3]. Importantly, potential
means to overcome these challenges include using the
internet to connect dispersed patients with expert care and
community engagement to help empower patients who feel
marginalized by the healthcare system [4–6].
One such rare disorder is congenital hypogonadotropic
hypogonadism (CHH, ORPHA174590). Based on a study
of French conscripts, CHH occurs in approximately one
in 4,000-10,000 [7]. It is clinically characterized by in-
complete (or absent) puberty and infertility resulting
from insufficient secretion or action of gonadotropin re-
leasing hormone (GnRH) - the master hormone of the
reproductive axis [8]. Genetic defects that affect olfac-
tory axon and olfactory bulb development, thus leading
to absent or defective sense of smell (anosmia or hypos-
mia), usually also affect the migration of neuroendocrine
GnRH cells from the nose to the brain during embryonic
life, thus leading to CHH. This condition is known as
the olfacto-genital syndrome or Kallmann syndrome
(ORPHA478). Some genetic and phenotypic overlap may
exist between isolated CHH and Kallmann syndrome,
yet patients with this syndrome are much more likely to
exhibit additional non-reproductive phenotypes (i.e.,
skeletal defects, renal agenesis, cleft lip/palate, deafness,
etc) than normosmic CHH patients. In the context of an
international network of leading clinicians/geneticists/
researchers focused on CHH [9], we have previously
developed patient partnerships and conducted a needs
assessment that leveraged engagement with patient
support groups, social media and online data collection
[10]. In parallel, we developed a web-based platform [9]
with resources for patients to find expert clinicians and
peer-to-peer support. Additionally, consensus guidelines
for the diagnosis and treatment of CHH were created
using an evidence-based approach [8].
Engagement and co-creation have been effectively used
in diverse fields including business, design and computer
science (i.e. user-centered design) as a means to spur
innovation, adoption and foster sustainability [11, 12].
Therefore, the aim of the present study was to partner
clinical experts and patients to co-create high-quality
patient education materials (PEM) that respond to the is-
sues and questions most important and relevant to pa-
tients. Secondary aims included evaluating the readability
of the PEM and end-user acceptability (i.e. understand-
ability and actionability) as well as to disseminate these
materials widely across different countries and cultures.
Methods
PEM development
A community based participatory research framework was
selected to guide the development of the patient education
material (PEM) for its relevance to patient empowerment
and health disparities [13]. The Patient advocacy Working
group of the European network focused on CHH (COST
Action BM1105, “GnRH Deficiency: Elucidation of the
neuroendocrine control of human reproduction”) [9]
worked closely with online patient community leaders (i.e.
moderators of online patient support sites) to identify key
PEM content areas and topics based on the most frequently
asked questions on social media sites (Additional file 1) as
well as from a previously conducted patient needs assess-
ment [10]. Clinical information was drawn from the
evidence-based consensus statement on the approach to
diagnosis and treatment of CHH [8]. The PEM develop-
ment was an iterative process (Fig. 1) involving multiple
stakeholders including patients, patient support groups,
clinicians and researchers spanning the fields of endocrin-
ology, andrology, nursing and genetics. At each step, input
and feedback were used to refine and modify the PEM.
Readability assessment
To assess reading level of the produced PEM, we sub-
jected the final version to several validated measures
evaluating readability: Flesch Reading Ease Formula
(evaluates sentence length and number of syllables per
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word), Flesch Kincaid Grade Level (converts the Flesch
reading ease formula to a grade level), Gunning Fox
Index (calculates a weighted average of the number of
words per sentence and long words to determine grade
level), Coleman Liau Index (uses number of characters
rather than syllables to determine grade level), Simple
Measure of Gobbledygook (SMOG, a modification of
the Gunning-Fog Index it calculates grade level based on
the number of words with 3 or more syllables) and the
Automated Readability Index (ratio of difficult words
and sentences to provide an estimated age range and
grade level) [14].
Fig. 1 Study Schema. PEM were co-created in a multi-step process. (a) Three main sources were used for PEM development. (b) Members of the
Patient Advocacy Working Group and patient collaborators identified topics for the PEM in an iterative process. (c) The initial draft was created
and revised based on patient input. (d) PEM (V2.0) was circulated to the Clinical Working Group and Genetics Working Group members for comment
and revised accordingly with patient validation in two rounds. (e) PEM (V4.0) were evaluated by patients recruited via social media (private/closed
Facebook groups), patient support meetings and via RareConnect [12]. (f) Following evaluation materials were culturally adapted and translated to 20
languages and distributed in avenues targeting healthcare professionals and patients. PEM: patient education materials, V: version
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End-user acceptability
To evaluate end-user perspectives of adults with CHH
(18 years and older), we used an online data collection
(SurveyGizmo™) and recruited a convenience sample of
patients via postings on closed/private CHH social media
group (Facebook™), as well as notifications in patient
support group meetings and RareConnect [15]. This social
media approach has been previously shown to be an ef-
fective means of recruitment for this rare disease patient
population [10]. The survey included questions on patient
demographics, past healthcare interactions and a brief
assessment of healthcare literacy that has been validated
against longer gold-standards metrics [16, 17].
After reviewing a pdf of the PEM, participants were
asked to complete the Patient Education Materials
Assessment Tool (PEMAT). This instrument was devel-
oped and validated by the U.S. Department of Health &
Human Services Agency for Health Research & Quality
to evaluate print and audiovisual educational materials
[18]. The unique aspect of the PEMAT is that it incor-
porates other additional elements that are not assessed
in traditional readability formulas. Patients select agree,
disagree or not-applicable for 17 items relating to under-
standability (the ability to process key messages) and 7
items on actionabilty (the ability to identify what one
can do to manage their condition). Items rated as agree
are given a score of 1, disagree 0 and cumulative scores
are expressed as a percentage (total score/possible total
X 100). Initial psychometric evaluation of the PEMAT
has demonstrated strong internal consistency, good reli-
ability, and initial evidence of construct validity [19].
Survey respondents were also given an opportunity to
provide free text comments (i.e. critiques and suggestions)
after completing the PEMAT questions.
Statistical analyses
The survey was alpha tested by patients in two rounds to
identify and correct any bugs prior to online launch.
Descriptive statistics were used to report summary find-
ings. To assess for potential response bias, Student’s t test
and Chi square test were used to compare demographic
characteristics of patients who completed the evaluation
with those who did not (partial completion). Thematic
analysis [20] was employed to codify and analyze open-
text responses NVivo11 (QSR International PSY Ltd.,
Melbourne Australia). The study was reviewed and
approved by the ethics committee of the University of
Lausanne and participants provided opt-in online consent.
Dissemination
The final step of this process was to disseminate the PEM
to reach the broadest possible audience. This included
using native speakers (i.e. expert clinicians, medical
translators) from across the European network to provide
versions in multiple languages. Particular attention was
given to finding appropriate terms and examples for the
translated PEM to make them culturally sensitive and
not simply verbatim translations. The final materials
will be distributed via traditional means to reach
healthcare professionals (i.e. peer-review publication,
professional meetings, individual providers’ websites,
and via the COST Action website [9]). In parallel PEMs
will be distributed via patient support groups including
online social media (Facebook™, Twitter™, patient blogs)
and publicized on internet platforms targeting the rare
disease community including the EURORDIS initiative
RareConnect [15].
Results
PEM development
Patient partnerships were used to identify key topics and
to target issues most important to patients as well as to
contribute content. A working group of the network
(Patient Advocacy Working Group) created a topic list
based on the consensus statement guidelines [8].
Additional items were drawn from focus group discus-
sions with patients held in the context of patient support
meetings (organized with patient leaders) as part of the
prior needs assessment [10] (Fig. 1A). Patient collabora-
tors also contributed lists of “frequently asked questions”
as well as topics that were recurrent in social media
threads and chat room discussions. Common questions
include: what causes CHH? Why didn’t I go through
puberty? Why can’t I smell? Is it curable? Can I have
children? Will my children have CHH? (see Additional
file 1). The drafted material version 1.0 (V1.0) went
through two subsequent revisions to refine language,
wording and selection of images via email and the PEM
was finalized in a face-to-face meeting prior to vetting
with the broader network (Fig. 1D). During this develop-
ment process it was sometimes challenging to balance
the input and feedback from clinicians and patients to
find the right balance and depth of information pro-
vided. Indeed, the face-to-face meeting was valuable for
arriving at consensus as opinions were conflicting at
times during the process and this was not easy to recon-
cile via email.
Readability levels
Readability was evaluated using 6 different validated
algorithms that are widely used to assess reading level
(Table 1). These employ different formulas that use word
length and complexity (i.e. the number of characters or
syllables in words, sentence length) to calculate an aver-
age grade level needed to understand the material. Most
patients read at an 8-9th grade reading level [21]. How-
ever, expert recommendation has identified the target
reading level at 6th grade (i.e. an 11 year-old child) [22].
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Two of the six algorithms scored the PEM at the target
grade level (Flesch Kincaid Grade Level: 5.9, Automated
Readability Index: 6.1). The mean grade level across
instruments was 8.0 (Table 1), indicating that more work
could be done to enhance readability. However, one
challenge in doing this is the number of complex words
(i.e. hypogonadism, cryptorchidism, infertility, etc) that
were deemed important by clinicians and patients alike
to include and define in lay terms.
Participants
Following patient alpha testing to identify and correct
bugs in the online evaluation, the survey was launched
and remained open for 8-weeks. During this period, 164
hits were registered. In total, 38 (23%) were “one-click”
entries who passed the opt-in consent but did not enter
demographic information. Responses of five participants
were excluded (age <18 years). More than a third of
respondents (58/164, 35%) partially completed the
evaluation (i.e. demographics up to viewing the PEM)
and 63 (38%) completed the entire PEM evaluation
(Fig. 1E). Characteristics of survey respondents are
depicted in Table 2. Notably, the predominance of male
responders (2:1) is keeping with the striking sexual
discordance in CHH [8]. Overall, patients were well-
educated (46/63, 73% achieving university or higher) and
by-and-large exhibited adequate health literacy (52/63,
82%). Notably, the mean age of diagnosis was 20.9 ±
6.4 years (range: 10–40, median 19) suggesting that
many patients are diagnosed quite late. In terms of prior
healthcare interactions, more than half (39/63, 62%) had
either a consultation or had received care at a specialized
academic center. In total, 36/63 (56%) had undergone
genetic testing yet only 12/63 (19%) reported having had
genetic counseling. We found no significant differences
between those who completed the evaluation and the
partial completers in terms of age (p = 0.30), sex (p = 0.37),
education (p = 0.94), health literacy (p = 0.15), or being
seen at an academic center (p = 0.09).
End-user acceptability
Patients gave the co-created PEM high scores on under-
standability (range: 88.9–97.5%, total mean: 94.2%)
which includes content, word choice/style, use of num-
bers, organization, layout/design and visual aids (Table 3).
The lowest rating (88.9%) was linked with being unclut-
tered which was commented on in the free text field by
three patients (i.e. having more white space). Similarly,
patients gave high scores on actionability (overall mean:
90.5%). The lowest score was assigned to explaining how
to use charts, graphs, or diagrams to take action and
manage the condition. Together the high scores on both
understandability and actionability indicate high end-
user acceptability.th=tlb=
Overall we received comments from 45/63 (71.4%) pa-
tients. Comments were coded according to themes and
sorted into categories. In total, 52 concepts were identified
Table 1 Summary of readability of co-created patient
education material
Summary statistics (5 pages, 203 sentences + images)
Word count = 1,654
Character count = 8,251
Complex words (≥3 syllables) = 268
Average characters per word = 5
Average words per sentence = 8.1
Instrument Score Grade level
Flesch Reading Ease 67.6 8-9th
Flesch-Kincaid Reading Level 5.9 6th
Gunning Fog Index 9.7 9-10th
Coleman Liau Index 8.8 8-9th
SMOG 9.7 9th
Automated Readability Index 6.1 6th
Mean 8.0 8th grade
Table 2 Patient characteristics (n = 63)
Sex n (%)
Male 42 (67%)
Female 21 (33%)
Age
18–29 13 (21%)
30–39 24 (38%)
40–49 17 (27%)
50–59 5 (8%)
60+ 4 (6%)
Children
None 42 (66%)
Biologic children 14 (22%)
Adopted children 7 (11%)
Education level
High school/vocational 17 (27%)
University 25 (40%)
Post-Graduate 21 (33%)
Health literacya
Adequate 52 (83%)
Inadequate 11 (17%)
Health experiences
Seen at academic center 39 (62%)
Had genetic testing 36 (57%)
Received genetic counseling 12 (19%)
ahealth literacy as assessed by [16, 17]
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from the 45 comments clustering into five categories
(Table 4). The most frequent sentiments were expressions
of thanks/approval (n = 19, 37%) followed by content (i.e.
treatment, infertility, and psychological aspects) n = 11
(21%), format (i.e. use of simple language, spacing) n = 10
(19%), personal concerns (n = 9, 17%) and three comments
underscored the importance of translating the PEM to
make it available to more patients.
Broad dissemination
Native speakers from across the European network made
culturally adapted translations. In some instances local
patients contributed to this translation and adaption
process. The translated PEMs required cultural adapta-
tion in some instances to help make them more relevant
for the target audience. For instance, a small cherry was
used to describe the size of the pituitary gland in the
Hungarian version, the Chinese version was altered as
“what you should know” was not culturally appropriate,
and terms describing depression were adapted in the
Polish version to enhance comprehension by the lay
public. Every effort was made to keep the entire content
of the PEM in the translated versions. When text length
expanded the images were adjusted accordingly to main-
tain a 5-page document. PEM are now available in 20
languages: English, Bulgarian, Chinese, Danish, Dutch,
French, German, Greek, Hebrew, Hungarian, Italian,
Korean, Polish, Portuguese, Romanian, Russian, Serbian,
Slovenian, Spanish, and Turkish (Additional file 2).
Dissemination plans will target healthcare professionals
Table 3 PEMAT Understandability and actionability of co-created
materials (n = 63)
PEMAT topic/category % agree
Content 92.1%
The material makes its purpose completely evident.
The material does not include information or content
that distracts from its purpose.
90.5%
Word choice & style 93.7%
The material uses common, everyday language.
Medical terms are used only to familiarize the
audience with the terms.
When used, medical terms are defined.
93.7%
The material uses the active voice (e.g. action verbs). 95.2%
Use of numbers 96.8%
Numbers appearing in the material are clear and
easy to understand.
The material does not expect the user to perform
calculations.
96.8%
Organization 93.7%
The material breaks or “chunks” information into
short sections.
The material’s sections have informative headers. 95.2%
The material presents information in a logical
sequence.
93.7%
The material provides a summary. 96.8%
Layout & design 95.2%
The material uses visual cues to draw attention to
key points.
Visual aids 95.2%
The material uses visual aids whenever they could
make content more easily understood.
The material’s visual aids reinforce rather than distract
from the content.
92.1%
The material’s visual aids have clear titles or captions. 95.2%
The material uses illustrations and photographs that
are clear and uncluttered.
88.9%
The material uses simple tables with short and clear
row and column headings.
97.5%
Total understandability 94.2%
Actionability 95.2%
The material clearly identifies at least one action
the user can take.
The material addresses the user directly when
describing actions.
92.1%
The material breaks down any action into
manageable, explicit steps.
92.5%
The material provides a tangible tool (e.g. checklists)
whenever it could help the user take action.
94.5%
The material explains how to use the charts, graphs,
tables, or diagrams to take actions
70.7%
The material uses visual aids whenever they could
make it easier to act on the instructions.
92.0%
Total actionability 90.5%
Table 4 Patient comments (n = 52) regarding the co-created
materials
Category Representative quote(s)
Thanks/approval
n = 19
• “I was very impressed and I think my friends
and family will find it easy to understand”
• “I am glad that there is a clear male/female
explanation. Often materials I find focus
predominantly on the males”
Content
n = 11
• “Elaborate on infertility and treatment”
• “I think you may be under discussing the
life-long emotional and psychological impact”
Formatting
n = 10
• “It felt like the pages were a bit full but I
can appreciate it must have been hard to
provide all the information necessary in
only 5 pages”
• “I think if there was a way to click on each
section for more detailed info that might help”
Personal concerns
n = 9
• “Other rare conditions that can also be evident
in patients with KS/CHH… …Explain that patients
can have additional illnesses besides KS/CHH”
• “It might be helpful to state that anosmia is
permanent. Of course it is most important to
focus on the hormonal component, but there
are definitely considerations in dealing with
anosmia as well”
Dissemination
n = 3
• “It would be great if you could translate into
several languages to reach more people”
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and patient-centric avenues such as social media and
patient support sites.
Discussion
The aim of this study was to engage patients and co-
create PEM that respond to what matters most to
patients. Subsequently, we evaluated the readability and
end-user acceptability of the PEM and sought to widely
disseminate the translated PEM across different countries
and cultures. Patients living with a rare disease face health
disparities [2] and patient engagement has been identified
as potential means to empower this patient population
[4–6]. Interestingly, patient engagement has recently been
gaining attention in the context of orphan drug develop-
ment [23]. However, the extent of patient engagement
varies widely. A 2014 systematic review of patient engage-
ment for research on rare diseases found engagement is
typically unidirectional - involving patients in consultative
roles and rarely in creative aspects or in terms of dissem-
ination [24]. The present study is unique in that we used a
participatory process to co-create PEM with patients; we
then evaluated the PEM produced by this collaboration,
and worked with patient groups to facilitate dissemination
to the largest possible audience.
We previously partnered with online patient community
leaders to identify the unmet health and informational
needs of patients with congenital hypogonadotropic hypo-
gonadism (CHH) and Kallmann syndrome [10]. In the
present study, the partnership was more clearly bi-
directional as patients were not simply providers of
opinions; rather they contributed directly in co-creating
the PEM in an iterative process. Notably, patient know-
ledge and expertise emerges from the day-to-day experi-
ences of living and coping with a rare condition and
therefore is inherently different from the expertise of
healthcare professionals [25]. Recently, a study examining
online exchanges among patients with rare adrenal disor-
ders found that information and support were central
elements in peer-to-peer exchanges [26]. Moreover, the
authors noted that patient-centered care could be en-
hanced by better integrating patient knowledge with the
care provided by professionals. In the present study,
developing the PEM was a true partnership that recognized
patient expertise as unique and complementary to expert
clinician knowledge. We believe that this co-creation con-
tributed to the high acceptability ratings by patients.
This evaluation process of the co-created PEM has
limitations. The evaluation was only conducted on the
English version. As such, the findings are not completely
transferable to the other translated versions despite the
inclusion of patients in developing some of the transla-
tions. Moreover, the additional validation step of back
translating the other versions was not conducted and
this could be viewed as a limitation. We only assessed
readability once the materials had been finalized, not
during the development process. In future studies, this
testing could be incorporated earlier in the development
process to improve the reading level of developed PEM.
While the evaluation was overwhelmingly positive and a
fairly sizeable sample was reached (for a rare disease
population), the patients completing the evaluation were
quite well-educated and exhibited high levels of health
literacy. Accordingly, our ability to draw inferences to a
broader population of lower literacy patients is limited.
This may reflect a bias of using a web-based survey - as
perhaps those using the web may have higher literacy
levels. However, recruiting sufficient numbers of patients
for rare disease studies has been a long-standing chal-
lenge [27, 28]. Therefore, we used a web-based approach
to overcome this barrier but note that such an approach
entails a potential risk of bias.
The Pew Foundation’s published report on health and
the internet indicates that patients living with a rare dis-
ease are internet power users who are most likely to seek
information about their condition online and find sup-
port from other patients using social media [29]. Based
on our previous success combining patient partnerships
and social media for the online needs assessment [10],
we employed a similar approach in the present study to
reach a relatively large sample (n = 63) over 8-weeks.
These experiences suggest that web-based platforms are
an effective means to reach and connect rare disease pa-
tients. Thus, the opportunities afforded by the internet
and social media may provide novel avenues for crowd-
sourcing solutions as well as offering a shared venue for
either clinician- or patient-led collaborations to improve
quality and add value to the healthcare system [5, 30].
The European Union Committee of Experts on Rare
Diseases (EUCERD) recommendations for Centers of
Expertise underscore the importance of collaboration
with patient organizations to provide information that is
at once accessible and adapted to patient needs [31]. For
many rare diseases, such as CHH/Kallmann syndrome,
formal organized patient support organizations do not
exist. As such, web-based approaches and social media
provide a critical means to broadly reach patients, identify
priorities and incorporate their perspectives and know-
ledge into care. This may be particularly advantageous in
light of the movement to form European Reference
Networks for rare diseases [32, 33].
The final step in this co-creation process was to engage
in bi-directional dissemination. This has been identified as
a shortcoming in much of the patient engagement re-
search conducted in the context of rare diseases [24].
Through the work of members of the Network and pa-
tients alike, materials were adapted and translated into 20
languages by native speakers. This collaborative process is
essential for ensuring that information provided to
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patients is culturally adapted and sensitive – a key element
for Centers of Expertise [31]. In parallel to traditional
healthcare professional outlets (e.g. scientific meetings,
peer-review publication) patient participants are distribut-
ing materials directly to other patients via social media
and postings on centralized patients sites [15]. The co-
created PEM (in multiple languages) is a critical compo-
nent of the list of patient resources available on the
website of the European network comprising a virtual
empowerment toolkit for patients and families [9].
Available information includes listings of international
specialized referral centers, genetic testing labs, clinical
trials, and peer-to-peer support as well as a portal for a
patient registry. We are utilizing both professional-
oriented avenues and more patient-oriented social
media outlets to hopefully reach unprecedented num-
bers of patients and clinicians and overcome traditional
roadblocks of implementation into practice [34–36].
Conclusions
Partnering with patients enabled co-creation of high-
quality PEM while social media and web-based data
collection facilitated timely evaluation by a dispersed pa-
tient population. We believe that partnering with expert
patients was an empowering experience and provides
valuable contributions for developing patient-centered
approaches to care. We envision this work will serve as
a roadmap for those wishing to engage in a co-creation
process and will help inform projects aimed at improv-
ing care for patients living with a rare disease.
Additional files
Additional file 1: Questions frequently asked by patients on the social
media patient support site. (PDF 51 kb)
Additional file 2: Patient Education Materials. (PDF 3856 kb)
Abbreviations
CHH: Congenital hypogonadotropic hypogonadism; EUCERD: European
Union Committee of Experts on Rare Diseases; EURORDIS: European
Organization for Rare Diseases; COST: European Cooperation in Science and
Technology; PEM: Patient education materials; PEMAT: Patient education
materials assessment tool; SMOG: Simple measure of Gobbledygook
Acknowledgements
The authors wish to thank the patients who generously gave their time in
helping to develop the patient education materials and we acknowledge
the Working Group members of COST Action BM1105 for their
contributions. Special thanks to Ms. Virginia Hughes for her critical input
during the development process, Prof. Linan Cheng of the Shanghai
Institute of Planned Parenthood Research for her validation of the Chinese
translations and Ms. Özlem Firat for her help in coordinating the translated
materials. This work was supported by the Rare Disease Foundation and
the BC Children’s Hospital Foundation (# 17-26) and COST Action BM1105.
Funding
This work was supported by the COST Action BM1105 and received funding from
the Rare Disease Foundation and the BC Children’s Hospital Foundation (# 17-26).
Availability of data and materials
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study.
Authors’ contributions
AD conceived the study and participated in study design, conduct, analyses
and drafted the manuscript. RQ, NP and NS helped draft the educational
materials with patients. All authors helped revise the materials and contributed
to developing culturally relevant translations. All authors read and approved the
final manuscript.
Competing interests
The authors have no financial or non-financial competing interests to declare.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study (protocol #233/13) was reviewed and approved by the Commission
Cantonale d’ethique de la recherche sur l’être humain which is the institutional
review board (Ethics Committee) associated with the University of Lausanne. All
survey participants provided opt-in electronic consent prior to completing the
online evaluation.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Endocrinology, National Institute of Endocrinology, C. Davila
University of Medicine and Pharmacy, Bucharest 050474, Romania.
2Deptartment of Clinical Sciences & Community Health and the Division of
Endocrine and Metabolic Diseases & Laboratory of Endocrine and Metabolic
Research, University of Milan, Milan, Italy. 3Ospedale San Luca, IRCCS Istituto
Auxologico Italiano, Piazzale Brescia 20, 20149 Milan, Italy. 4Patient Advocacy
Working Group and the International Medical Interpreters Association,
Pyatigorsk, Russia. 5University Hospital Ghent Department of Pediatric
Endocrinology, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium.
6University of Medicine and Pharmacy “Iuliu Hatieganu”, 8, V Babes str.,
400012 Cluj-Napoca, Romania. 7Endocrinology, Diabetes & Obesity Service of
the Department of Pediatric Medicine and Surgery, Children’s Hospital of
Lausanne, Chemin de Montétan 16, 1004 Lausanne, Switzerland. 8Pediatric
Endocrinology and Metabolism Unit, Faculty of Health Sciences, Soroka
Medical Center, Ben-Gurion University of the Negev, PO Box 151IL-84101
Beer-Sheva, Israel. 9Laboratory of Endocrine Neurobiology of the Institute of
Experimental Medicine of the Hungarian Academy of Sciences, 43 Szigony
St., 1083 Budapest, Hungary. 10Department of Growth and Reproduction GR,
Rigshospitalet section 5064, Blegdamsvej 9, 2100 Copenhagen, Denmark.
11St. George’s Medical School of the University of London, Molecular &
Clinical Sciences Research Institute, Cell Biology & Genetics Research Centre,
Cranmer Terrace, London SW17 0RE, UK. 12Clinical Center of Endocrinology,
Medical University, 2 Zdrawe St, 1431 Sofia, Bulgaria. 13Autónoma University
of Madrid, Hospital La Paz Institute of Health Research (IdiPAZ),
Endocrinology and Nutrition Service of La Paz University Hospital, Castellana
261, 28046 Madrid, Spain. 14CICS-UBI, Health Sciences Research Centre,
University of Beira Interior, Covilha 6200-506, Portugal. 15Department of
Molecular Genetics of the Cyprus Institute of Neurology and Genetics, P.O.
Box 23462, Nicosia, Cyprus. 16Department of Pediatric Endocrinology and
Rheumatology, Poznan University of Medical Sciences, Szpitalna Street 27/33,
60-572 Poznan, Poland. 17School of Medicine, University of Belgrade & Clinic
of Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center
Belgrade, dr Subotic 13, 11000 Belgrade, Serbia. 18Department of Clinical
Sciences & Community Health, University of Milan, Milan, Italy. 19Division of
Endocrine and Metabolic Diseases & Laboratory of Endocrine and Metabolic
Research, Milan, Italy. 20Department of Endocrinology, Hospital S João,
Alameda Hernani Monteiro, 4200 Porto, Portugal. 21University of Lausanne
and the Endocrinology, Diabetes & Metabolism Service, Lausanne University
Hospital, Rue du Bugnon 46, Lausanne 1011, Switzerland. 22School of
Medicine, University of Belgrade, dr Subotic 8, 11000 Belgrade, Serbia.
23University of Newcastle-upon-Tyne, Institute of Genetic Medicine and the
Royal Victoria Infirmary, Newcastle-upon-Tyne NE1 3BZ, UK. 24Division of
Badiu et al. Orphanet Journal of Rare Diseases  (2017) 12:57 Page 8 of 9
Pediatric Endocrinology, Paedi Center for specialized Pediatrics, Nicosia,
Cyprus. 25St George’s University of London Medical School at the University
of Nicosia, Nicosia, Cyprus. 26Patient Advocacy Working Group, London, UK.
27University Medical Centre Ljubljana, University Children’s Hospital, Dept. of
pediatric endocrinology, diabetes and metabolism, Bohoriceva ul. 20, 1000
Ljubljana, Slovenia. 28Service d’Endocrinologie et des Maladies de la
Reproduction, Hôpital Bicêtre, Le Kremlin-Bicêtre 94275, France. 29University
of Lausanne, Institute of Higher Education & Research in Healthcare and the
Endocrinology, Diabetes & Metabolism Service of the Lausanne University
Hospital, Route de la Corniche 10, Lausanne 1010, Switzerland.
Received: 14 December 2016 Accepted: 6 March 2017
References
1. EURORDIS. The voice of 12,000 patients: Experiences and expectations of
rare disease patients on diagnosis and care in Europe. France: Boulogne-
Billancourt; 2009.
2. Holtzclaw Williams P. Policy framework for rare disease health disparities.
Policy Polit Nurs Pract. 2011;12:114–8.
3. Cohen JS, Biesecker BB. Quality of life in rare genetic conditions: a
systematic review of the literature. Am J Med Genet A. 2010;152A:1136–56.
4. Ayme S, Kole A, Groft S. Empowerment of patients: lessons from the rare
diseases community. Lancet. 2008;371:2048–51.
5. Vicari S, Cappai F. Health activism and the logic of connective action. A
case study of rare disease patient organisations. Inf Commun Soc.
2016;19:1653–71.
6. Sofolahan-Oladeinde Y, Mullins CD, Baquet CR. Using community-based
participatory research in patient-centered outcomes research to address
health disparities in under-represented communities. J Comp Effectiveness
Res. 2015;4:515–23.
7. Fromantin M, Gineste J, Didier A, Rouvier J. Impuberism and hypogonadism
at induction into military service. Statistical study. Problemes Actuels
d’Endocrinologie et de Nutr. 1973;16:179–99.
8. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dode C, Dunkel L, Dwyer AA,
Giacobini P, Hardelin JP, Juul A, et al. Expert consensus document: European
Consensus Statement on congenital hypogonadotropic hypogonadism–
pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2015;11:547–64.
9. COST Action BM1105 [http://www.gnrhnetwork.eu/]. Accessed 14 Mar 2017.
10. Dwyer AA, Quinton R, Morin D, Pitteloud N. Identifying the unmet health
needs of patients with congenital hypogonadotropic hypogonadism using
a web-based needs assessment: implications for online interventions and
peer-to-peer support. Orphanet J Rare Dis. 2014;9:83.
11. Crawford MJ, Rutter D, Manley C, Weaver T, Bhui K, Fulop N, Tyrer P.
Systematic review of involving patients in the planning and development
of health care. BMJ. 2002;325:1263.
12. Greenhalgh T, Jackson C, Shaw S, Janamian T. Achieving research impact
through co-creation in community-based health services: literature review
and case study. Milbank Q. 2016;94:392–429.
13. Wallerstein N, Duran B. Community-based participatory research contributions
to intervention research: the intersection of science and practice to improve
health equity. Am J Public Health. 2010;100 Suppl 1:S40–46.
14. CheckText [http://www.readabilityformulas.com]. Accessed 14 Mar 2017.
15. RareConnect [https://www.rareconnect.org]. Accessed 14 Mar 2017.
16. Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with
inadequate health literacy. Fam Med. 2004;36:588–94.
17. Chew LD, Griffin JM, Partin MR, Noorbaloochi S, Grill JP, Snyder A, Bradley
KA, Nugent SM, Baines AD, Vanryn M. Validation of screening questions for
limited health literacy in a large VA outpatient population. J Gen Intern
Med. 2008;23:561–6.
18. Shoemaker SJ, Wolf MS, Brach C, (Prepared by Abt Associates IuCNHI: The
Patient Education Materials Assessment Tool (PEMAT) and User’s Guide. In
Book The Patient Education Materials Assessment Tool (PEMAT) and User’s
Guide (Editor ed.^eds.). Maryland: Agency for Healthcare Research and
Quality; 2013.
19. Shoemaker SJ, Wolf MS, Brach C. Development of the Patient Education
Materials Assessment Tool (PEMAT): a new measure of understandability
and actionability for print and audiovisual patient information. Patient Educ
Couns. 2014;96:395–403.
20. Saldana J. Coding manual for qualitative researchers. Thousand Oaks,
CA: Sage; 2009.
21. Safeer RS, Keenan J. Health literacy: the gap between physicians and
patients. Am Fam Physician. 2005;72:463–8.
22. Doak CC, Doak LG, Root JH. Teaching Patients with Low Literacy Skills. 2nd
ed. Philadelphia, PA: J.B. Lippincott Company; 1996.
23. Bronstein MG, Kakkis ED. Patients as key partners in rare disease drug
development. Nat Rev Drug Discov. 2016;15:731–2.
24. Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, Fleurence R,
Hickam DH. A systematic review of approaches for engaging patients for
research on rare diseases. J Gen Intern Med. 2014;29 Suppl 3:S788–800.
25. Hartzler A, Pratt W. Managing the personal side of health: how patient
expertise differs from the expertise of clinicians. J Med Internet Res.
2011;13:e62.
26. Kauw D, Repping-Wuts H, Noordzij A, Stikkelbroeck N, Hermus A, Faber M.
The contribution of online peer-to-peer communication among patients
with adrenal disease to patient-centered care. J Med Internet Res.
2015;17:e54.
27. Kruer MC, Steiner RD. The role of evidence-based medicine and clinical trials
in rare genetic disorders. Clin Genet. 2008;74:197–207.
28. Watson MS, Epstein C, Howell RR, Jones MC, Korf BR, McCabe ER, Simpson JL.
Developing a national collaborative study system for rare genetic diseases.
Genet Med. 2008;10:325–9.
29. Fox S. Peer-to-peer healthcare: many people - especially those living with
chronic or rare diseases - use online connections to supplement
professional medical advice. Washington, D.C.: Pew Internet; 2011.
30. Nambisan P, Nambisan S. Models of consumer value cocreation in health
care. Health Care Manag Rev. 2009;34:344–54.
31. (EUCERD) EUCoEoRD: Recommendations on quality criteria for centres of
expertise for rare diseases in member states. In: Book Recommendations on
Quality Criteria for Centres of Expertise for Rare Diseases in Member States
(Editor ed.^eds.). City; 2011.
32. Diseases EUCoEoR. Recommendations to the European Commission and the
Member States on European Reference Networks for Rare Diseases. 2013.
33. European Reference Network [http://ec.europa.eu/health/rare_diseases/
european_reference_networks/erf/index_en.htm]. Accessed 14 Mar 2017.
34. Sung NS, Crowley Jr WF, Genel M, Salber P, Sandy L, Sherwood LM, Johnson
SB, Catanese V, Tilson H, Getz K, et al. Central challenges facing the national
clinical research enterprise. JAMA. 2003;289:1278–87.
35. Thornicroft G, Lempp H, Tansella M. The place of implementation science in
the translational medicine continuum. Psychol Med. 2011;41:2015–21.
36. Bellgarda MI, Sleemanc MW, Guerrerod FD, Fletcher S, Baynam G, Goldblatt
J, Rubinstein Y, Bell C, Groft S, Barreroa R, et al. Rare disease research
roadmap: navigating the bioinformatics and translational challenges for
improved patient health outcomes. Health Policy Technol. 2014;3:325–35.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Badiu et al. Orphanet Journal of Rare Diseases  (2017) 12:57 Page 9 of 9
